AKEBIA THERAPEUTICS, INC. Earnings Per Share (Basic)
AKEBIA THERAPEUTICS, INC. (AKBA) reported Earnings Per Share (Basic) of -$0.03 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-05
- AKEBIA THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.03.
- AKEBIA THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$0.03, a 200.00% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-09-30 was $0.00.
- AKEBIA THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-06-30 was $0.00.
- AKEBIA THERAPEUTICS, INC. earnings per share, basic for fiscal 2025 was -$0.02.
- AKEBIA THERAPEUTICS, INC. earnings per share, basic for fiscal 2024 was -$0.33.
- AKEBIA THERAPEUTICS, INC. earnings per share, basic for fiscal 2023 was -$0.28.
- AKEBIA THERAPEUTICS, INC. earnings per share, basic for fiscal 2022 was -$0.52.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.03 10-Q · filed 2026-08-05 | -$0.07 10-Q · filed 2026-08-05 | ||||||
| 2026-03-31 | -$0.03 10-Q · filed 2026-05-07 | |||||||
| 2025-12-31 | -$0.02 10-K · filed 2026-02-26 | |||||||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-10 | $0.03 10-Q · filed 2025-11-10 | ||||||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-05 | $0.03 10-Q · filed 2026-08-05 | ||||||
| 2025-03-31 | $0.03 10-Q · filed 2026-05-07 | |||||||
| 2024-12-31 | -$0.33 10-K · filed 2026-02-26 | |||||||
| 2024-09-30 | -$0.10 10-Q · filed 2025-11-10 | -$0.14 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$0.22 10-Q · filed 2025-11-10 | |||||
| 2024-06-30 | -$0.04 10-Q · filed 2025-08-07 | -$0.13 10-Q · filed 2025-08-07 | ||||||
| 2024-03-31 | -$0.09 10-Q · filed 2025-05-08 | |||||||
| 2023-12-31 | -$0.28 10-K · filed 2026-02-26 | |||||||
| 2023-09-30 | -$0.08 10-Q · filed 2024-11-07 | -$0.14 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$0.28 10-Q · filed 2024-11-07 | |||||
| 2023-06-30 | -$0.06 10-Q · filed 2024-08-08 | -$0.20 10-Q · filed 2024-08-08 | ||||||
| 2023-03-31 | -$0.15 10-Q · filed 2024-05-09 | -$0.14 10-Q · filed 2023-05-08 | ||||||
| 2022-12-31 | -$0.52 10-K · filed 2024-03-14 | -$0.51 10-K · filed 2023-03-10 | ||||||
| 2022-09-30 | -$0.29 10-Q · filed 2023-11-08 | -$0.28 10-Q · filed 2022-11-03 | -$0.13 derived: net income ÷ weighted average shares · filed 2023-11-08 | -$0.48 10-Q · filed 2023-11-08 | -$0.47 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $0.16 10-K/A · filed 2023-08-28 | -$0.19 10-K/A · filed 2023-08-28 | -$0.18 10-Q · filed 2022-08-04 | |||||
| 2022-03-31 | -$0.35 10-K/A · filed 2023-08-28 | |||||||
| 2021-12-31 | -$1.70 10-K/A · filed 2023-08-28 | |||||||
| 2021-09-30 | -$0.34 10-Q · filed 2022-11-03 | -$0.85 derived: net income ÷ weighted average shares · filed 2022-11-03 | -$1.30 10-Q · filed 2022-11-03 | |||||
| 2021-06-30 | -$0.51 10-Q · filed 2022-08-04 | -$0.97 10-Q · filed 2022-08-04 | ||||||
| 2021-03-31 | -$0.45 10-Q · filed 2022-05-09 | |||||||
| 2020-12-31 | -$2.78 10-K/A · filed 2023-08-28 | -$2.77 10-K · filed 2022-03-01 | ||||||
| 2020-09-30 | -$0.42 10-Q · filed 2021-11-04 | -$2.18 10-Q · filed 2021-11-04 | ||||||
| 2020-06-30 | -$1.28 10-Q · filed 2021-08-05 | -$1.78 10-Q · filed 2021-08-05 | ||||||
| 2019-12-31 | -$2.36 10-K · filed 2022-03-01 | |||||||
| 2017-12-31 | $0.33 10-K · filed 2019-03-26 | $0.26 10-K · filed 2018-03-12 | ||||||
| 2017-09-30 | -$0.49 10-K · filed 2019-03-26 | |||||||
| 2017-06-30 | -$0.53 10-K · filed 2019-03-26 | |||||||
| 2017-03-31 | -$1.15 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |